AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16078807 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconferenced educational detailing (TED) CME
Number of subjects: 61
Study 16078807 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 61
Study 11549099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast (Ariflo) 15 mg, single and repeat doses, taken before or between meals
Number of subjects: 5
Study 11549099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast (Ariflo) 30 mg, repeat doses, taken after meals
Number of subjects: 5
Study 9663727 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 169
Study 9663727 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily
Number of subjects: 169
Study 7908358 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-dose warfarin (1 mg daily for 6 weeks, adjusted to maintain INR of 1.3 to 1.9)
Number of subjects: 311
Study 7908358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 7908358 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-dose warfarin
Number of subjects: 311
Study 7908358 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-dose warfarin and Placebo
Number of subjects: 311
Study 3043251 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic non-ionic contrast medium, iohexol (omnipaque)
Number of subjects: 0
Study 3043251 — intervention group
Group type: COMPARATOR
Intervention: Meglumine-sodium-diatrizoate (urografin)
Number of subjects: 0
Study 1852753 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Activity Assessment Tool
Number of subjects: 40
Study 363751 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate (P) 50 mg
Number of subjects: 27
Study 363751 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 27
Study 363751 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium (F) 600 mg
Number of subjects: 27
Study 363751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of P and F (P50 + F50)
Number of subjects: 27
Study 363751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of P and F (P200 + F50)
Number of subjects: 27
Study 363751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of P and F (P200 + F200)
Number of subjects: 27
Study 363751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of P and F (P200 + F600)
Number of subjects: 27
Study 363751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31678307 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic bronchoscopy (RB)
Number of subjects: 60
Study 31678307 — intervention group
Group type: COMPARATOR
Intervention: Electromagnetic navigational bronchoscopy (EMN)
Number of subjects: 60
Study 31678307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin bronchoscope with radial EBUS (UTB-rEBUS)
Number of subjects: 60
Study 31018988 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT (combined pediatrician and behavioral clinician arms)
Number of subjects: 1871
Study 31018988 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1871
Study 28410107 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature Sensitive Label Fusion (FSLP) method for brain image segmentation
Number of subjects: 0
Study 26209747 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly ergocalciferol (50,000 IU) supplementation
Number of subjects: 115
Study 24102055 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (3 cups daily for 14 weeks)
Number of subjects: 0
Study 24102055 — intervention group
Group type: COMPARATOR
Intervention: Water regimen (control group)
Number of subjects: 0
Study 21562068 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/statin
Number of subjects: 21794
Study 21562068 — intervention group
Group type: COMPARATOR
Intervention: statin
Number of subjects: 21794
Study 19544246 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured technique (N = 51)
Number of subjects: 99
Study 19544246 — intervention group
Group type: COMPARATOR
Intervention: Blind technique (N = 48)
Number of subjects: 99
Study 19544246 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 99
Study 17921019 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum ferritin levels
Number of subjects: 824
Study 17921019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary iron intake
Number of subjects: 824
Study 15508793 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA)
Number of subjects: 74
Study 15508793 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AA)
Number of subjects: 74
Study 11557163 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 12
Study 11557163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9272339 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPwc vaccine
Number of subjects: 0
Study 9272339 — intervention group
Group type: COMPARATOR
Intervention: DTaP vaccine
Number of subjects: 0
Study 9272339 — intervention group
Group type: COMPARATOR
Intervention: DT vaccine
Number of subjects: 0
Study 9272339 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockholm I Trial
Number of subjects: 0
Study 9272339 — intervention group
Group type: COMPARATOR
Intervention: Italian Trial
Number of subjects: 0
Study 7930197 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional echocardiography
Number of subjects: 35
Study 7930197 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional echocardiography
Number of subjects: 35
Study 3235234 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (for men)
Number of subjects: 60
Study 3235234 — intervention group
Group type: COMPARATOR
Intervention: Sober (for women)
Number of subjects: 60
Study 30974182 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification cataract extraction (PECE) by high-volume surgeons (more than 350 cases/year)
Number of subjects: 35880
Study 30974182 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification cataract extraction (PECE)
Number of subjects: 35880
Study 30974182 — intervention group
Group type: EXPERIMENTAL
Intervention: Small‐incision cataract surgery (SICS)
Number of subjects: 35880
Study 30974182 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patient age
Number of subjects: 35880
Study 30974182 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon experience
Number of subjects: 35880
Study 28093441 — intervention group
Group type: EXPERIMENTAL
Intervention: Premium brand name cigarettes
Number of subjects: 81
Study 28093441 — intervention group
Group type: COMPARATOR
Intervention: Value brand name cigarettes
Number of subjects: 81
Study 26269563 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication and treatment with antioxidants
Number of subjects: 976
Study 22762359 — intervention group
Group type: EXPERIMENTAL
Intervention: Two small diameter implants (SDI) ‐ retained overdenture (study group)
Number of subjects: 30
Study 22762359 — intervention group
Group type: COMPARATOR
Intervention: Non‐intervention group (control group)
Number of subjects: 30
Study 21511222 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding (defined according to STEEPLE minor or major criteria)
Number of subjects: 3148
Study 21511222 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding within 30 days
Number of subjects: 3148
Study 21511222 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding after 30 days
Number of subjects: 3148
Study 21511222 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial Infarction (MI)
Number of subjects: 3148
Study 21511222 — intervention group
Group type: EXPERIMENTAL
Intervention: MI within 30 days
Number of subjects: 3148
Study 21511222 — intervention group
Group type: EXPERIMENTAL
Intervention: MI after 30 days
Number of subjects: 3148
Study 18463993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan and quinidine (DM/Q) 30 mg/30 mg, twice a day
Number of subjects: 31
Study 18463993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 17063976 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion (CIVS) of lorazepam
Number of subjects: 13
Study 17063976 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of lorazepam
Number of subjects: 13
Study 17063976 — intervention group
Group type: EXPERIMENTAL
Intervention: CIVS administration
Number of subjects: 13
Study 14513074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program (moderate physical activity and diet changes for 3 months)
Number of subjects: 21
Study 14513074 — intervention group
Group type: COMPARATOR
Intervention: Lean controls (baseline comparison)
Number of subjects: 21
Study 14513074 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese intervention group
Number of subjects: 21
Study 14513074 — intervention group
Group type: COMPARATOR
Intervention: Obese control group
Number of subjects: 21
Study 14513074 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 21
Study 11311625 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 27
Study 11311625 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 27
Study 9863096 — intervention group
Group type: EXPERIMENTAL
Intervention: Liangxue Piyan granule No. 2 (LPG)
Number of subjects: 96
Study 9863096 — intervention group
Group type: COMPARATOR
Intervention: Fufang Qingdai Capsule (FQC)
Number of subjects: 96
Study 7929700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tests of flexibility and programming (Spatial Learning with Self-Set Goals, Sorting)
Number of subjects: 53
Study 7929700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition/Energy deficit on the Neurobehavioral Rating Scale
Number of subjects: 53
Study 7929700 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 53
Study 7929700 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional intelligence tests
Number of subjects: 53
Study 7929700 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography findings
Number of subjects: 53
Study 7929700 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Score
Number of subjects: 53
Study 2459525 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/day)
Number of subjects: 21
Study 2459525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31023352 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Cognitive Therapy for Anxiety (ACTA) - six 60-90 min sessions and a booster session
Number of subjects: 48
Study 31023352 — intervention group
Group type: COMPARATOR
Intervention: Group Cognitive Behaviour Therapy (CBT) - eight 2-h sessions and a booster session
Number of subjects: 48
Study 29492934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 80
Study 29492934 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg
Number of subjects: 80
Study 29492934 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 26076096 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific intervention in preferred language
Number of subjects: 222
Study 26076096 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific intervention
Number of subjects: 222
Study 26076096 — intervention group
Group type: EXPERIMENTAL
Intervention: Materials in preferred language
Number of subjects: 222
Study 23753523 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric (ECC) exercise
Number of subjects: 0
Study 23753523 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric (CONC) exercise
Number of subjects: 0
Study 23753523 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged ECC training
Number of subjects: 0
Study 23753523 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged CONC training
Number of subjects: 0
Study 23753523 — intervention group
Group type: COMPARATOR
Intervention: Whey protein supplementation
Number of subjects: 0
Study 21970061 — intervention group
Group type: COMPARATOR
Intervention: Standard vocal therapy (Group I, n=33)
Number of subjects: 66
Study 21970061 — intervention group
Group type: EXPERIMENTAL
Intervention: Larynx compression vocal therapy (Group II, n=33)
Number of subjects: 66
Study 20160680 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVI brachytherapy
Number of subjects: 21
Study 20160680 — intervention group
Group type: EXPERIMENTAL
Intervention: MammoSite brachytherapy
Number of subjects: 21
Study 20160680 — intervention group
Group type: COMPARATOR
Intervention: 3D‐CRT
Number of subjects: 21
Study 16445445 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof Natural IOL (model SN60AT)
Number of subjects: 37
Study 16445445 — intervention group
Group type: COMPARATOR
Intervention: Acrysof IOL (model SA60AT)
Number of subjects: 37
Study 15536840 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionator therapy (n = 14)
Number of subjects: 25
Study 15536840 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 25
Study 11320947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Education Program (NEP)
Number of subjects: 172
Study 11320947 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-based Stress Reduction Clinic Program (SRC)
Number of subjects: 172
Study 11320947 — intervention group
Group type: COMPARATOR
Intervention: Usual Supportive Care (UC)
Number of subjects: 172
Study 9301391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's solution 25 ml kg‐1 over 30 min (in males)
Number of subjects: 21
Study 9301391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's solution 25 ml kg‐1 over 30, 45, and 80 min (in females)
Number of subjects: 21
Study 1376962 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride (1.5 mg/day)
Number of subjects: 35
Study 1376962 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride (3.0 mg/day)
Number of subjects: 35
Study 3884469 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metoprolol
Number of subjects: 32
Study 3884469 — intervention group
Group type: COMPARATOR
Intervention: Injection sclerotherapy
Number of subjects: 32
Study 30400725 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Number of subjects: 193
Study 30400725 — intervention group
Group type: COMPARATOR
Intervention: 4-L polyethylene glycol (PEG)
Number of subjects: 193
Study 29754811 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Exposure Therapy and Exercise
Number of subjects: 42
Study 29754811 — intervention group
Group type: COMPARATOR
Intervention: Fall Prevention Education
Number of subjects: 42
Study 27020000 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency potentiated with infrared light and fractional bipolar radiofrequency (combined approach)
Number of subjects: 22
Study 27020000 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated quadrant)
Number of subjects: 22
Study 27020000 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Bipolar radiofrequency potentiated with infrared light and fractional bipolar radiofrequency)
Number of subjects: 22
Study 25004496 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapy for 12 weeks
Number of subjects: 32
Study 25004496 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 32
Study 21988617 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone (60 mg/day) for 12 months
Number of subjects: 158
Study 21988617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 21988617 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone (60 mg/day)
Number of subjects: 158
Study 19854632 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS reminder
Number of subjects: 26
Study 19854632 — intervention group
Group type: COMPARATOR
Intervention: No SMS reminder (Control)
Number of subjects: 26
Study 18030233 — intervention group
Group type: EXPERIMENTAL
Intervention: Bravo pH capsule
Number of subjects: 66
Study 18030233 — intervention group
Group type: COMPARATOR
Intervention: Nasally placed pH catheter
Number of subjects: 66
Study 16118573 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) ingestion (4 mL.kg.15 min of 6%)
Number of subjects: 15
Study 16118573 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) ingestion
Number of subjects: 15
Study 12374444 — intervention group
Group type: EXPERIMENTAL
Intervention: Protestant participants in a work context
Number of subjects: 0
Study 12374444 — intervention group
Group type: EXPERIMENTAL
Intervention: Male Protestant participants in a work setting
Number of subjects: 0
Study 12374444 — intervention group
Group type: EXPERIMENTAL
Intervention: Male Protestant participants in a nonwork setting
Number of subjects: 0
Study 12374444 — intervention group
Group type: EXPERIMENTAL
Intervention: Women participants (both Protestant and non-Protestant)
Number of subjects: 0
Study 10428349 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler energy (CDE)
Number of subjects: 19
Study 10428349 — intervention group
Group type: EXPERIMENTAL
Intervention: CDE during treatment
Number of subjects: 19
Study 9651714 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic clinical parameters, ECG, and exercise test
Number of subjects: 200
Study 9651714 — intervention group
Group type: EXPERIMENTAL
Intervention: ST depression > or = 0.1 mV
Number of subjects: 200
Study 9651714 — intervention group
Group type: EXPERIMENTAL
Intervention: Low maximum workload at exercise test
Number of subjects: 200
Study 9651714 — intervention group
Group type: EXPERIMENTAL
Intervention: ST T-changes at early exercise test
Number of subjects: 200
Study 1681365 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of Ty21a vaccine
Number of subjects: 20543
Study 1681365 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated capsules of Ty21a vaccine
Number of subjects: 20543
Study 1681365 — intervention group
Group type: COMPARATOR
Intervention: Placebo (liquid formulation)
Number of subjects: 20543
Study 6345649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepenzolate bromide (MZB) 50 mg, taken 4 times daily for 48 hours
Number of subjects: 70
Study 6345649 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken 4 times daily for 48 hours
Number of subjects: 70
Study 6345649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepenzolate bromide (MZB)
Number of subjects: 70
Study 6345649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31575091 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 µg) and Coenzyme Q10 (200 mg) daily for four years
Number of subjects: 443
Study 31575091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 30278569 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil
Number of subjects: 102
Study 30278569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 27080343 — intervention group
Group type: EXPERIMENTAL
Intervention: Honeybee LAB microbiome (a mixture of 9 Lactobacillus spp. and 4 Bifidobacterium spp.)
Number of subjects: 22
Study 27080343 — intervention group
Group type: EXPERIMENTAL
Intervention: Honeybee LAB microbiome
Number of subjects: 22
Study 27080343 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 22
Study 24622750 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect infant supplementation (400 mg iodine to the mother, placebo to the infant)
Number of subjects: 241
Study 24622750 — intervention group
Group type: COMPARATOR
Intervention: Direct infant supplementation (100 mg iodine to the infant, placebo to the mother)
Number of subjects: 241
Study 24622750 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect infant supplementation
Number of subjects: 241
Study 24622750 — intervention group
Group type: COMPARATOR
Intervention: Direct infant supplementation
Number of subjects: 241
Study 24622750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 241
Study 23158178 — intervention group
Group type: EXPERIMENTAL
Intervention: CA4P arm (carboplatin/paclitaxel with CA4P)
Number of subjects: 80
Study 23158178 — intervention group
Group type: COMPARATOR
Intervention: Control arm (carboplatin/paclitaxel without CA4P)
Number of subjects: 80
Study 20218995 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 IU oxytocin bolus and 30 IU infusion
Number of subjects: 720
Study 20218995 — intervention group
Group type: COMPARATOR
Intervention: 5 IU oxytocin bolus and placebo
Number of subjects: 720
Study 19029269 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet gel (APG)
Number of subjects: 64
Study 19029269 — intervention group
Group type: COMPARATOR
Intervention: Gelatine (CONT)
Number of subjects: 64
Study 15812262 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg/day)
Number of subjects: 280
Study 15812262 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (40 mg/day)
Number of subjects: 280
Study 12458821 — intervention group
Group type: EXPERIMENTAL
Intervention: Coxibs (celecoxib and rofecoxib)
Number of subjects: 0
Study 10357338 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of alkalinized lidocaine with 0 microg phenylephrine (Group 1)
Number of subjects: 81
Study 10357338 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of alkalinized lidocaine with 50 microg phenylephrine (Group 2)
Number of subjects: 81
Study 10357338 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of alkalinized lidocaine with 100 microg phenylephrine (Group 3)
Number of subjects: 81
Study 10357338 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of alkalinized lidocaine with 200 microg phenylephrine (Group 4)
Number of subjects: 81
Study 8546442 — intervention group
Group type: EXPERIMENTAL
Intervention: CH + MCT/LCT regimen
Number of subjects: 24
Study 8546442 — intervention group
Group type: COMPARATOR
Intervention: CH regimen
Number of subjects: 24
Study 1672870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/ACTH treatment
Number of subjects: 0
Study 7033673 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 161
Study 7033673 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 161
Study 7033673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161